US Fights J&J Bid To Ax Blood Cancer Patent
The U.S. government has rejected a Johnson & Johnson unit's attacks on a patented treatment for a rare kind of blood cancer, telling a London court that it has found "issue...To view the full article, register now.
Already a subscriber? Click here to view full article